Jaguar Health Reports Q3 Revenue Decline and GAAP Net Loss
Jaguar Health, Inc. (JAGX) reported third-quarter financial results characterized by a significant decline in revenue and substantial net losses. The company posted a GAAP earnings per share (EPS) of -$9.23, while total revenue fell to $2.34 million, representing a 24% decrease compared to the same period last year. Despite these headwinds, the company is focusing on long-term regulatory milestones. Jaguar Health aims to file a New Drug Application (NDA) for its MVID treatment by mid-2027, with potential U.S. approval by late 2027. The therapeutic target seeks to reduce parenteral support requirements by up to 48%.

Topics: earnings report EBITDA net loss revenue decline
Read the full article at Seeking Alpha
Part of the story Lexeo Therapeutics GAAP EPS of -$0.43 misses by $0.10 (3 articles)